Rallybio to acquire Candid Therapeutics [Yahoo! Finance]
Rallybio Corporation (RLYB)
Company Research
Source: Yahoo! Finance
US-based biotechnology company Rallybio has entered a definitive agreement to acquire Candid Therapeutics through a merger transaction. Following completion, the combined entity will operate as Candid Therapeutics and list on Nasdaq under the "CDRX" ticker symbol. As part of the merger, Candid has secured more than $505m in gross proceeds from a concurrent private financing round. The round is supported by institutional investors such as RA Capital Management; Venrock Healthcare Capital Partners; accounts advised by entities such as Cormorant Asset Management, Foresite Capital, and Janus Henderson Investors; additional mutual funds and others. The combined cash balance at closing is projected to fund operations through 2030. The capital will be used to progress Candid's T-cell engager (TCE) portfolio through key milestones. This includes planned initiation and clinical data readouts from Phase II studies for cizutamig, a TCE targeting B-cell maturation antigen (BCMA), in my
Show less
Read more
Impact Snapshot
Event Time:
RLYB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RLYB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RLYB alerts
High impacting Rallybio Corporation news events
Weekly update
A roundup of the hottest topics
RLYB
News
- Rallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio Corporation - RLYBBusiness Wire
- Rallybio Corporation (RLYB) M&A Call Prepared Remarks Transcript [Seeking Alpha]Seeking Alpha
- Rallybio Announces Positive Data for RLYB116 Phase 1 Study Demonstrating Complete and Sustained Inhibition of Terminal ComplementBusiness Wire
- Rallybio Announces Reverse Stock Split of Common Stock [Yahoo! Finance]Yahoo! Finance
- Rallybio Announces Reverse Stock Split of Common StockBusiness Wire
RLYB
Earnings
- 5/8/25 - In-Line
RLYB
Sec Filings
- 3/3/26 - Form SCHEDULE
- 2/23/26 - Form 4
- 2/20/26 - Form 4
- RLYB's page on the SEC website